Publications dans lesquelles il/elle collabore avec José Benito (77)

2017

  1. Monocytes phenotype and cytokine production in human immunodeficiency virus-1 infected patients receiving a modified vaccinia ankara-based HIV-1 vaccine: Relationship to CD300 molecules expression

    Frontiers in Immunology, Vol. 8, Núm. JUL

2016

  1. IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection

    Liver International, Vol. 36, Núm. 9, pp. 1258-1266

  2. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

  3. Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients

    Journal of Translational Medicine, Vol. 14, Núm. 1

  4. Short communication: CXCL12 rs1029153 polymorphism is associated with the sustained virological response in HIV/Hepatitis C virus-coinfected patients on Hepatitis C Virus therapy

    AIDS Research and Human Retroviruses, Vol. 32, Núm. 3, pp. 226-231

2015

  1. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1

    Journal of Antimicrobial Chemotherapy, Vol. 70, Núm. 6, pp. 1833-1842

  2. TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients

    Journal of Clinical Virology, Vol. 65, pp. 62-67

2014

  1. European mitochondrial haplogroups are not associated with hepatitis C virus (HCV) treatment response in HIV/HCV-coinfected patients

    HIV Medicine, Vol. 15, Núm. 7, pp. 425-430

  2. PPARγ2 Pro12Ala polymorphism is associated with sustained virological response in HIV/HCV-coinfected patients under HCV therapy

    Journal of Acquired Immune Deficiency Syndromes, Vol. 67, Núm. 2, pp. 113-119

2013

  1. A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients

    Journal of Antimicrobial Chemotherapy, Vol. 68, Núm. 4, pp. 915-921

  2. Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients

    AIDS, Vol. 27, Núm. 2, pp. 163-173

  3. Central memory CD4 T cells are associated with incomplete restoration of the CD4 T cell pool after treatment-induced long-term undetectable HIV viraemia

    Journal of Antimicrobial Chemotherapy, Vol. 68, Núm. 11, pp. 2616-2625

  4. HIV exposed seronegative individuals show antibodies specifically recognizing native HIV envelope glycoprotein

    AIDS, Vol. 27, Núm. 9, pp. 1375-1385

  5. HIV gag-specific immune response mediated by double negative (CD3+CD4-CD8-) T cells in HIV-exposed seronegative individuals

    Journal of Medical Virology, Vol. 85, Núm. 2, pp. 200-209

  6. HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy

    AIDS, Vol. 27, Núm. 8, pp. 1231-1238

  7. IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients

    Journal of Viral Hepatitis, Vol. 20, Núm. 5, pp. 358-366

  8. Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library

    European Journal of Immunology, Vol. 43, Núm. 2, pp. 499-509

  9. Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients

    AIDS, Vol. 27, Núm. 5, pp. 687-696

  10. The changing face of hepatitis C in the new era of direct-acting antivirals

    Antiviral Research

  11. Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir

    Antiviral Therapy, Vol. 18, Núm. 5, pp. 709-715